GSBS Student Publications

Title

Inhibition of Epstein-Barr virus (EBV) release from the P3HR-1 Burkitt's lymphoma cell line by a monoclonal antibody against a 200,000 dalton EBV membrane antigen

UMMS Affiliation

Graduate School of Biomedical Sciences; Department of Pharmacology and Medicine

Date

5-1-1985

Document Type

Article

Medical Subject Headings

Animals; Antibodies, Monoclonal; Antigens, Surface; Antigens, Viral; Burkitt Lymphoma; Cell Line; Epitopes; Herpesvirus 4, Human; Humans; Immunosuppressive Agents; Mice; Mice, Inbred BALB C; Molecular Weight; Neutralization Tests; Phosphonoacetic Acid

Disciplines

Life Sciences | Medicine and Health Sciences

Abstract

In raising murine hybridoma antibodies against Epstein-Barr virus (EBV)-induced membrane antigens (MA), we found one antibody that blocked the release of infectious EBV from cultured P3HR-1 cells. This monoclonal antibody (mAb) recognized a 200 kD, phosphonoacetic acid-sensitive (late) MA, and did not directly neutralize virus without complement. When this mAb was added to 33 degrees C-cultured, spontaneously EBV-producing P3HR-1 cells, the intracellular expression of viral capsid antigen and infectious virus was not inhibited, but the appearance of infectious virus in the culture medium was significantly reduced. The duration of this suppression was dependent upon the concentration of the mAb, an effect being observed to a 1:4 X 10(5) titer of the ascites mAb preparation. A more acute effect of suppression of EBV release was observed in a second model of 12-o-tetradecanoyl phorbol-13-acetate and n-butyrate induction of EBV in 37 degrees C-cultured P3HR-1 cells. Again, intracellular infectious virus production was not inhibited, but the level of infectious virus in the culture medium was significantly reduced as early as 1 and 2 d of culture with antibody. This effect was reversed within 31 h after replacement of mAb-containing medium with fresh medium. This description of antibody-mediated inhibition of EBV release might lead to the characterization of another form of immune defense for the control of EBV infections.

Rights and Permissions

Citation: J Exp Med. 1985 May 1;161(5):1097-111.

Related Resources

Link to Article in PubMed

Journal Title

The Journal of experimental medicine

PubMed ID

2580934